Voting Results of Cosmo's 2025 AGM
Rhea-AI Summary
Positive
- Approved dividend of €2.05 per share, representing a 2.5% increase from previous year
- Strong shareholder participation with 52.07% of total outstanding shares represented at AGM
- All voting items received shareholder approval, indicating strong alignment with management
Negative
- None.
Dublin, Ireland--(Newsfile Corp. - May 30, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) announced that its shareholders approved all voting items at today’s Ordinary Annual General Meeting. A total of 9,135,061 ordinary shares of the share capital of Cosmo were represented at this general meeting of shareholders. These shares make up
Among others, the shareholders of Cosmo approved a dividend of €2.05 per share, a dividend distribution increase of
Alessandro Della Chà, Chairman of Cosmo, commented: “On behalf of the entire Board, I would like to thank all our shareholders for their continued trust and their participation in this year’s Annual General Meeting. We remain committed to delivering long-term value, and we are grateful to have them on this journey with us.”
Giovanni Di Napoli, CEO of Cosmo, added: “We are now looking forward to providing our stakeholders, including financial analysts and media representatives, with further insights into our ongoing and future projects at our upcoming Investor Day on 1 July in Zurich.”
About Cosmo
Cosmo Pharmaceuticals N.V. is committed to revolutionizing healthcare and transforming people’s lives by researching and developing innovative products that tackle unfulfilled healthcare demands. As a pharmaceutical company, Cosmo is active in the areas of Healthtech/AI, dermatology, gastroenterology and contract manufacturing & development. For the commercialization and distribution of its products, Cosmo collaborates with leading partners worldwide, including Medtronic and Sun Pharma. Founded in 1997, Cosmo is headquartered in Dublin (Ireland) and has offices also in San Diego (USA), and Lainate/Rome/Catania (Italy). The Company has approximately 330 employees at the end of 2024, all dedicated to making a significant impact in the field of healthcare. For more information, please visit www.cosmopharma.com.
Upcoming Events
| Jefferies Healthcare Conference, New York | June 3-5, 2025 |
| Investor Day, Zurich | July 1, 2025 |
| 2025 Half-Year Results and Report | July 23, 2025 |
For further information, please contact:
Attachments
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/253966
FAQ
What dividend did Cosmo Pharmaceuticals (CMOPF) approve for 2025?
When is the ex-dividend date for Cosmo's 2025 dividend?
What was the shareholder participation rate at Cosmo's 2025 AGM?
When is Cosmo Pharmaceuticals' Investor Day 2025?
Were all voting items approved at Cosmo's 2025 AGM?
